What does this research mean for the field?

Trimetazidine synergistically enhances the cytotoxicity of cisplatin in HeLa cervical cancer cells while simultaneously reducing its toxicity in healthy human liver fibroblast cells. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To investigate the cytotoxic and synergistic effects of trimetazidine, alone and combined with cisplatin, against HeLa cervical cancer cells and healthy human liver fibroblasts.

September 2, 2026Cumhuriyet Science JournalOpen Access

Trimetazidine Enhances the Cytotoxicity of Cisplatin in HeLa Cells: An in vitro Study on a Potential Synergistic Drug Interaction

View Full Paper

Ask AI

Bookmark

Authors

EÖElif Özgüler ÖKÖzge Kesgin SŞSerap Şahin‐Bölükbaşı

Discussion

Member takes

Overview

In vitro study reveals trimetazidine enhances cisplatin cytotoxicity in cervical cancer cells while protecting liver cells, suggesting a synergistic strategy for combination chemotherapy.

Key Points

To investigate the cytotoxic and synergistic effects of trimetazidine, alone and combined with cisplatin, against HeLa cervical cancer cells and healthy human liver fibroblasts.
Exposed HeLa cervical cancer cells and T0063 healthy human liver fibroblast cells to varying concentrations (1–200 µM) of trimetazidine, cisplatin, and their combinations.
Measured cell viability across 24, 48, and 72 hours using the MTT colorimetric assay and evaluated safety using the Selectivity Index.
Trimetazidine monotherapy showed negligible cytotoxic activity in both cell lines across all durations (IC50 > 200 µM).
Co-administration of trimetazidine with cisplatin at 24 and 48 hours significantly increased cytotoxicity in HeLa cells while reducing toxicity in T0063 liver cells, raising the Selectivity Index from 2.66 to 9.91 at 24 hours before synergy diminished by 72 hours.

Cite This Study

Özgüler et al. (2026) studied this question.

synapsesocial.com/papers/6a97e25ec562ede874ec682a https://doi.org/10.17776/csj.1913625

View Full Paper

Ask AI

Bookmark

September 2, 2026Cumhuriyet Science JournalOpen Access

Trimetazidine Enhances the Cytotoxicity of Cisplatin in HeLa Cells: An in vitro Study on a Potential Synergistic Drug Interaction

View Full Paper

Ask AI

Bookmark

Authors

EÖElif Özgüler ÖKÖzge Kesgin SŞSerap Şahin‐Bölükbaşı

Discussion

Member takes

Overview

In vitro study reveals trimetazidine enhances cisplatin cytotoxicity in cervical cancer cells while protecting liver cells, suggesting a synergistic strategy for combination chemotherapy.

Key Points

To investigate the cytotoxic and synergistic effects of trimetazidine, alone and combined with cisplatin, against HeLa cervical cancer cells and healthy human liver fibroblasts.
Exposed HeLa cervical cancer cells and T0063 healthy human liver fibroblast cells to varying concentrations (1–200 µM) of trimetazidine, cisplatin, and their combinations.
Measured cell viability across 24, 48, and 72 hours using the MTT colorimetric assay and evaluated safety using the Selectivity Index.
Trimetazidine monotherapy showed negligible cytotoxic activity in both cell lines across all durations (IC50 > 200 µM).
Co-administration of trimetazidine with cisplatin at 24 and 48 hours significantly increased cytotoxicity in HeLa cells while reducing toxicity in T0063 liver cells, raising the Selectivity Index from 2.66 to 9.91 at 24 hours before synergy diminished by 72 hours.

Cite This Study

Özgüler et al. (2026) studied this question.

synapsesocial.com/papers/6a97e25ec562ede874ec682a https://doi.org/10.17776/csj.1913625

View Full Paper

Ask AI

Bookmark